FDA Advises of Adverse Effects from New Cholesterol Drugs

FDA asks Sanofi and Regeneron to conduct an assessment of the potential for a cholesterol drug they are codeveloping to cause neurocognitive adverse events.

Leave a Reply

Your email address will not be published. Required fields are marked *